Tianeptine: A Dangerous and Unapproved Drug Sold as a “Cure”
What you need to knowThe dangers of tianeptine
FDA warns that tianeptine is sold online and even at gas stations as a supposed treatment for depression, anxiety, pain, and opioid withdrawal. But don’t be fooled — this drug is not approved by the FDA for any medical use in the U.S. and has been linked to serious harm, addiction, and even death.
What You Need to Know
Tianeptine is NOT safe or legal in the U.S. — it’s often sold as a dietary supplement, but it’s neither a dietary ingredient nor an approved drug. It has been falsely marketed to improve mood, brain function, or help with opioid withdrawal — with no scientific support. And reports of overdose and poisoning have skyrocketed — from just 4 cases in 2013 to about 350 in 2024.
Health Risks Include
- Agitation, confusion, vomiting
- High blood pressure, rapid heartbeat
- Slowed or stopped breathing
- Coma and death
- Withdrawal symptoms that mimic opioid withdrawal
Many users take doses far higher than what’s used in other countries, increasing the danger. Mixing tianeptine with other drugs (like antidepressants or anti-anxiety meds) makes the risk even worse.
Protect Yourself
- Avoid any product containing tianeptine — in pill, powder, or liquid form.
- Don’t self-treat serious conditions like depression or opioid dependence.
- Talk to a health professional for safe, approved treatments.
- Report harmful effects at MedWatch or call 1-800-332-1088.
If you suspect poisoning, call the Poison Help Line at 1-800-222-1222. If you or someone you love needs help with substance use, visit the Find Treatment website or call 1-800-662-HELP (4357).
Just because a product is easy to buy doesn’t mean it’s safe. Tianeptine is dangerous and unapproved — don’t risk your life for an unproven fix.
Sterile Drug Manufacturing Violations at Daewoo Pharmaceutical
FDA Cracks Down on Sterile Drug Manufacturing Violations The U.S. Food and Drug Administration (FDA) has issued a warning letter to Daewoo Pharmaceutical Co., Ltd. in Busan, South Korea, citing serious and widespread violations of current Good Manufacturing Practices...
The FDA Orphan Drug Program
Incentives for Rare Disease Drug Development The FDA’s Orphan Drug Program was established to encourage the development of drugs for rare diseases that affect fewer than 200,000 people in the U.S. Because these diseases often lack market incentives due to small...
FDA Alert: Abiomed Impella Blood Pump Controller
Abiomed Impella blood pump controllers Controller May Fail to Detect Device Abiomed has issued an urgent safety notice for its Automated Impella Controller (AIC) due to a potentially serious issue where the system may fail to detect the Impella blood pump when...